Querol-Ribelles JM, Tenias JM, Grau E, et al. Plasma D-dimmer levels correlate with outcomes in patients with commuity-acquired pneumonia[J]. Chest, 2004, 126(4): 1087-1092.
Günther A, Mosavi P, Heinemann S, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome[J]. Am J Respir Crit Care Med, 2000, 161(2 pt 1): 454-462.
[ 4 ] Gabazza EC, Taquchi O, Yamakami T, et al. Evaluating Prethrombotic state in lung cancer using molecular markers[J]. Chest, 1993, 103(1): 196-200.
[ 9 ] Pavey SJ, Hawson GA, Matsh NA. Impact of the fibrinolytio ehzymesystem on prognosis and survival associated with non-small cell lung carcinoma[J]. Blood Coagul Fibrinolysis, 2001, 12(1): 51-58.
[16]
Taguchi O, Gabazza EC , Yasui H, et al. Prognostic signification of plasma D-dimmer levels in patients with lung cancer[J]. Thorax, 1997, 52(6): 563-565.
[17]
Buccheri G, Torchio P, Ferrigno D. Plasma level of D-dimmer in lung carcinoma: clinical and prognostic significance[J]. Cancer, 2003, 97(12): 3044-3052.
[18]
Wouters EF, Groenewegen KH, Dentener MA, et al. Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations[J]. Proc Am Thorac Soc, 2007, 4(8): 626-634.
Kawada H, Katsura H, Kamimura M, et al. Coagulation activity in the airways of asthmatic patients[J]. Nihon Kokyuki Gakkai Zasshi, 2003, 41(9): 620-625.
Shilon Y, Shitrit AB, Rudensky B, et al. A rapit quantitative D-dimmer assay at admission correlates with the severity of community acquired pneumonia[J]. Blood Coagulation Fibrinolysis, 2003, 14(8): 745-748.
